Dicyclomine Should Not Be Used for Long-Term Therapy
Dicyclomine is not recommended for long-term use due to lack of safety data beyond short-term trials, concerning anticholinergic effects with chronic use, and the absence of evidence supporting sustained efficacy.
Evidence Base and Limitations
The 2022 AGA guidelines 1 provide only a conditional recommendation for antispasmodics (including dicyclomine) in IBS, with low certainty evidence. Critically, the guideline explicitly notes that available studies lack long-term safety data and did not consistently report adverse events leading to discontinuation. The evidence base consists primarily of short-term trials (typically 2-8 weeks), with the longest documented study being just 2 weeks 2.
Key Safety Concerns with Prolonged Use
Anticholinergic burden accumulates with chronic use, particularly problematic in:
- Older adults: Increased risk of cognitive impairment, falls, constipation, and urinary retention
- Patients with constipation-predominant symptoms: The guidelines specifically warn that "regular use in constipation may be limited due to its anticholinergic effects" 1
- Cardiovascular considerations: Tachycardia and potential for unmasking underlying cardiac conditions
Common Anticholinergic Side Effects
The most frequently reported adverse effects include 1:
- Dry mouth
- Dizziness
- Blurred vision
- Constipation 3
- Potential worsening of gastroesophageal reflux in supine position 4
Clinical Approach: Use Intermittently, Not Continuously
The appropriate strategy is as-needed dosing for acute symptom flares, not daily maintenance therapy:
- Use dicyclomine 10-20 mg up to 4 times daily only during symptomatic periods
- Target postprandial abdominal pain episodes (though this specific indication lacks RCT support 1)
- Reassess need after 2-4 weeks of continuous use
- If symptoms require daily therapy beyond 4-8 weeks, pursue alternative management strategies
When to Avoid Entirely
Per FDA labeling 5, dicyclomine is contraindicated in:
- Infants <6 months (risk of respiratory complications and death)
- Nursing mothers
- Glaucoma patients
- Obstructive uropathy or GI obstruction
- Myasthenia gravis
- Severe ulcerative colitis
- Reflux esophagitis
Critical Pitfalls
Never administer intravenously: A 2025 case report 6 documented thrombotic complications from inadvertent IV administration—this route is absolutely contraindicated
Monitor for anticholinergic toxicity: Particularly in elderly patients or those on multiple medications with anticholinergic properties (cumulative burden)
Recognize limited efficacy data: The effect size for individual antispasmodics like dicyclomine is difficult to interpret due to small study numbers 1, and no serious adverse events were reported primarily because studies were too short to detect them
Position-dependent effects: Dicyclomine may paradoxically worsen reflux in supine position while improving upright symptoms 4
Alternative Long-Term Strategies
If chronic daily therapy is needed for IBS symptoms:
- Consider neuromodulators (TCAs, SNRIs) with better long-term safety profiles
- Evaluate for specific IBS subtypes requiring targeted therapy (rifaximin for IBS-D, linaclotide for IBS-C)
- Address underlying visceral hypersensitivity with gut-brain axis therapies
- Implement dietary modifications (low FODMAP)
The absence of long-term safety data is itself evidence against chronic use—the burden of proof for safety lies with demonstrating no harm over extended periods, which has never been established for dicyclomine.